ロード中...
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0–1 were treated with eribulin-LF either on day 1 every 21 days...
保存先:
| 出版年: | Br J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6461749/ https://ncbi.nlm.nih.gov/pubmed/30679780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0377-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|